E
Eric Kuhn
Researcher at Broad Institute
Publications - 35
Citations - 5605
Eric Kuhn is an academic researcher from Broad Institute. The author has contributed to research in topics: Targeted mass spectrometry & Selected reaction monitoring. The author has an hindex of 24, co-authored 32 publications receiving 4401 citations. Previous affiliations of Eric Kuhn include Millennium Pharmaceuticals & Harvard University.
Papers
More filters
Journal ArticleDOI
Proteogenomic characterization of human colon and rectal cancer
Bing Zhang,Jing Wang,Xiaojing Wang,Jing Zhu,Qi Liu,Zhiao Shi,Matthew C. Chambers,Lisa J. Zimmerman,Kent Shaddox,Sangtae Kim,Sherri R. Davies,Sean Wang,Pei Wang,Christopher R. Kinsinger,Robert Rivers,Henry Rodriguez,R. Reid Townsend,Matthew J. Ellis,Steven A. Carr,Steven A. Carr,David L. Tabb,Robert J. Coffey,Robbert J.C. Slebos,Daniel C. Liebler,Michael A. Gillette,Karl R. Klauser,Eric Kuhn,D. R. Mani,Philipp Mertins,Karen A. Ketchum,Amanda G. Paulovich,Jeffrey R. Whiteaker,Nathan Edwards,Peter B. McGarvey,Subha Madhavan,Daniel W. Chan,Akhilesh Pandey,Ie Ming Shih,Hui Zhang,Zhen Zhang,Heng Zhu,Gordon Whiteley,Steven J. Skates,Forest M. White,Douglas A. Levine,Emily S. Boja,Tara Hiltke,Mehdi Mesri,Kenna M. Shaw,Stephen E. Stein,David Fenyö,Tao Liu,Jason E. McDermott,Samuel H. Payne,Karin D. Rodland,Richard D. Smith,Paul A. Rudnick,Michael Snyder,Yingming Zhao,Xian Chen,David F. Ransohoff,Andrew N. Hoofnagle,Melinda E. Sanders,Yue Wang,Li Ding +64 more
TL;DR: Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
Journal ArticleDOI
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Hui Zhang,Tao Liu,Zhen Zhang,Samuel H. Payne,Bai Zhang,Jason E. McDermott,Jian-Ying Zhou,Vladislav A. Petyuk,Li Chen,Debjit Ray,Shisheng Sun,Feng Yang,Lijun Chen,Jing Wang,Punit Shah,Seong Won Cha,Paul Aiyetan,Sunghee Woo,Yuan Tian,Marina A. Gritsenko,Therese R. W. Clauss,Caitlin H. Choi,Matthew E. Monroe,Stefani N. Thomas,Song Nie,Chaochao Wu,Ronald J. Moore,Kun-Hsing Yu,David L. Tabb,David Fenyö,Vineet Bafna,Yue Wang,Henry Rodriguez,Emily S. Boja,Tara Hiltke,Robert Rivers,Lori J. Sokoll,Heng Zhu,Ie Ming Shih,Leslie Cope,Akhilesh Pandey,Bing Zhang,Michael Snyder,Douglas A. Levine,Richard D. Smith,Daniel W. Chan,Karin D. Rodland,Steven A. Carr,Michael A. Gillette,Karl R. Klauser,Eric Kuhn,D. R. Mani,Philipp Mertins,Karen A. Ketchum,Ratna R. Thangudu,Shuang Cai,Mauricio Oberti,Amanda G. Paulovich,Jeffrey R. Whiteaker,Nathan Edwards,Peter B. McGarvey,Subha Madhavan,Pei Wang,Gordon Whiteley,Steven J. Skates,Forest M. White,Christopher R. Kinsinger,Mehdi Mesri,Kenna M. Shaw,Stephen E. Stein,Paul A. Rudnick,Michael Snyder,Yingming Zhao,Xian Chen,David F. Ransohoff,Andrew N. Hoofnagle,Daniel C. Liebler,Melinda E. Sanders,Zhiao Shi,Robbert J.C. Slebos,Lisa J. Zimmerman,Sherri R. Davies,Li Ding,Matthew J. Ellis,R. Reid Townsend +84 more
TL;DR: A view of how the somatic genome drives the cancer proteome and associations between protein and post-translational modification levels and clinical outcomes in HGSC is provided.
Journal ArticleDOI
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach
Steven A. Carr,Susan E. Abbatiello,Bradley L. Ackermann,Christoph H. Borchers,Bruno Domon,Eric W. Deutsch,Russell P. Grant,Andrew N. Hoofnagle,Ruth Hüttenhain,Ruth Hüttenhain,John M. Koomen,Daniel C. Liebler,Tao Liu,Brendan MacLean,D. R. Mani,Elizabeth Mansfield,Hendrik Neubert,Amanda G. Paulovich,Lukas Reiter,Olga Vitek,Ruedi Aebersold,Leigh Anderson,Robert Bethem,Josip Blonder,Emily S. Boja,Julianne Cook Botelho,Michael T. Boyne,Ralph A. Bradshaw,Alma L. Burlingame,Daniel W. Chan,Hasmik Keshishian,Eric Kuhn,Christopher R. Kinsinger,Jerry S.H. Lee,Jerry S.H. Lee,Sang Won Lee,Robert L. Moritz,Juan A. Oses-Prieto,Nader Rifai,James C. Ritchie,Henry Rodriguez,Pothur R. Srinivas,Raymond R. Townsend,Jennifer E. Van Eyk,Gordon Whiteley,Arun P. Wiita,Susan T. Weintraub +46 more
TL;DR: A workshop was held at the National Institutes of Health with representatives from the multiple communities developing and employing targeted MS assays and defined three tiers of assays distinguished by their performance and extent of analytical characterization.
Journal ArticleDOI
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.
Suhas Vasaikar,Chen Huang,Xiaojing Wang,Vladislav A. Petyuk,Sara R. Savage,Bo Wen,Yongchao Dou,Yun Zhang,Zhiao Shi,Osama A. Arshad,Marina A. Gritsenko,Lisa J. Zimmerman,Jason E. McDermott,Therese R. W. Clauss,Ronald J. Moore,Rui Zhao,Matthew E. Monroe,Yi-Ting Wang,Matthew C. Chambers,Robbert J.C. Slebos,Ken S. Lau,Qianxing Mo,Li Ding,Matthew J. Ellis,Mathangi Thiagarajan,Christopher R. Kinsinger,Henry Rodriguez,Richard D. Smith,Karin D. Rodland,Karin D. Rodland,Daniel C. Liebler,Tao Liu,Bing Zhang,Akhilesh Pandey,Amanda G. Paulovich,Andrew N. Hoofnagle,D. R. Mani,Daniel W. Chan,David F. Ransohoff,David Fenyö,David L. Tabb,Douglas A. Levine,Emily S. Boja,Eric Kuhn,Forest M. White,Gordon Whiteley,Heng Zhu,Hui Zhang,Ie Ming Shih,Jasmin H. Bavarva,Jeffrey R. Whiteaker,Karen A. Ketchum,Karl R. Clauser,Kelly V. Ruggles,Kimberly Elburn,Linda Hannick,Mark A. Watson,Mauricio Oberti,Mehdi Mesri,Melinda E. Sanders,Melissa Borucki,Michael A. Gillette,Michael Snyder,Nathan Edwards,Negin Vatanian,Paul A. Rudnick,Peter B. McGarvey,Philip Mertins,R. Reid Townsend,Ratna R. Thangudu,Robert Rivers,Samuel H. Payne,Sherri R. Davies,Shuang Cai,Stephen E. Stein,Steven A. Carr,Steven J. Skates,Subha Madhavan,Tara Hiltke,Xian Chen,Yingming Zhao,Yue Wang,Zhen Zhang +82 more
TL;DR: Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens, which suggested glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade.
Journal ArticleDOI
Quantification of C‐reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C‐labeled peptide standards
TL;DR: C‐reactive protein (CRP), a diagnostic marker of rheumatoid arthritis (RA), was detected in serum samples taken from patients with either erosive or nonerosive RA and compared to healthy individuals using an immunoassay.